GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Asset Turnover
中文

Affymax (Affymax) Asset Turnover : 0.01 (As of Jun. 2014)


View and export this data going back to 2006. Start your Free Trial

What is Affymax Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Affymax's Revenue for the three months ended in Jun. 2014 was $0.04 Mil. Affymax's Total Assets for the quarter that ended in Jun. 2014 was $5.92 Mil. Therefore, Affymax's Asset Turnover for the quarter that ended in Jun. 2014 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Affymax's annualized ROE % for the quarter that ended in Jun. 2014 was 2,035.00%. It is also linked to ROA % through Du Pont Formula. Affymax's annualized ROA % for the quarter that ended in Jun. 2014 was 486.81%.


Affymax Asset Turnover Historical Data

The historical data trend for Affymax's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Asset Turnover Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.66 0.38 0.80 0.02

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - 0.01

Competitive Comparison of Affymax's Asset Turnover

For the Biotechnology subindustry, Affymax's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Affymax's Asset Turnover falls into.



Affymax Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Affymax's Asset Turnover for the fiscal year that ended in Dec. 2013 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2013 )/( (Total Assets (A: Dec. 2012 )+Total Assets (A: Dec. 2013 ))/ count )
=1.369/( (118.217+7.443)/ 2 )
=1.369/62.83
=0.02

Affymax's Asset Turnover for the quarter that ended in Jun. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2014 )/( (Total Assets (Q: Mar. 2014 )+Total Assets (Q: Jun. 2014 ))/ count )
=0.042/( (6.463+5.384)/ 2 )
=0.042/5.9235
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Affymax  (OTCPK:AFFY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Affymax's annulized ROE % for the quarter that ended in Jun. 2014 is

ROE %**(Q: Jun. 2014 )
=Net Income/Total Stockholders Equity
=28.836/1.417
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(28.836 / 0.168)*(0.168 / 5.9235)*(5.9235/ 1.417)
=Net Margin %*Asset Turnover*Equity Multiplier
=17164.29 %*0.0284*4.1803
=ROA %*Equity Multiplier
=486.81 %*4.1803
=2,035.00 %

Note: The Net Income data used here is four times the quarterly (Jun. 2014) net income data. The Revenue data used here is four times the quarterly (Jun. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Affymax's annulized ROA % for the quarter that ended in Jun. 2014 is

ROA %(Q: Jun. 2014 )
=Net Income/Total Assets
=28.836/5.9235
=(Net Income / Revenue)*(Revenue / Total Assets)
=(28.836 / 0.168)*(0.168 / 5.9235)
=Net Margin %*Asset Turnover
=17164.29 %*0.0284
=486.81 %

Note: The Net Income data used here is four times the quarterly (Jun. 2014) net income data. The Revenue data used here is four times the quarterly (Jun. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Affymax Asset Turnover Related Terms

Thank you for viewing the detailed overview of Affymax's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010